Pancreatic cancer is one of the most lethal human tumors [1] , with a 5-year survival rate of less than 5%. The lack of effective treatments is still one of the greatest challenges in clinical chemotherapy. A good prognostic marker for predicting the treatment response may improve the chemotherapeutic efficacy.
K-ras mutation is found in 90% pancreatic adenocarcinomas [2, 3] , and the most common mutations are located at codon 12, 13, or 61 as shown in the Sanger Registry (http://www.sanger.ac.uk). Considering its important role in cell survival and proliferation, K-ras has been extensively studied in recent years. Previous studies revealed that K-ras gene mutations cause excessive activation of K-RAS/ RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways [4] [5] [6] [7] [8] [9] .
There are increasing evidences showing that K-ras mutational status can be regarded as a predictor of anti-epidermal growth factor (EGFR) monoclonal antibodies in colorectal cancer and non-small-cell lung cancer (NSCLC). Several recent phase 2 and 3 studies had demonstrated that mutant K-ras could be regarded as a predictor of poor response to panitumumab and cetuximab in colorectal cancer [10] .
However, the prognostic role of K-ras oncogenic mutation in patients who received cytotoxic chemotherapy is still under debate. Tsao et al. [11] reported that WT K-ras patients survived longer than K-ras mutant patients while treated with vinorelbine/cisplatin. Capelletti et al. [12] reported that patients with K-ras mutations had a worse prognosis and derived less benefit form adjuvant carboplatin/paclitaxel. However, Pickard et al. [13] and Rosty et al. [14] both proved that mutant K-ras did not correlate with disease progression while treated with 5-FU/folinic acid.
In the present study, we generated K-ras overexpressing clones with the four most common mutations (G12D, G12V, G12R and G13D) from human pancreatic cancer cell line Bxpc-3 with a wild-type (WT) egfr and K-ras. The chemotherapy sensitivity and its potential mechanism were also investigated in these clones to assess the predictive role of K-ras status in cytotoxic chemotherapy in pancreatic cancer.
Materials and methods

K-Ras-pAcGFP1-C3 plasmid construction
The full sequence of K-ras gene carrying BamH I and Xho I sites, synthetized by Genewiz (Shanghai, China), was inserted into pAcGFP1-C3 vector (Clontech Laboratories, Inc, Mountain View, CA, USA) to construct K-Ras-pAcGFP1-C3. K-ras gene and pAcGFP1-C3 vector were digested by BamH I and Xho I restriction enzyme, followed by isolation and purification, and then ligated with T4 DNA ligase. Ligation products were transformed to E. coli DH5α, and then spread on 2×YT medium culture plate with kanamycin, which were cultured at 37°C overnight. Positive clones were picked up and screened by PCR, identified via digesting by BamH I and Xho I restriction enzyme and sequencing the inserted fragments.
Transfection and screening Bxpc-3 cells with stable expression of K-ras
Bxpc-3 cells (Chinese Academy of Sciences, Shanghai, China) were cultured in RPMI1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco) at 37°C in a humidified atmosphere of a 5% CO 2 . Bxpc-3 cells express wild-type (WT) egfr and K-ras, which can be obtained from the Wellcome Trust Sanger Institute Catalogue of Somatic Mutations in Cancer (COSMIC) website (http://www.sanger. ac.uk/cosmic/). 1×10 6 cells were seeded in a 12-well plate, and 12 h later, plasmids were transfected into cells with lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in RPMI1640 without FBS according to the manufacturer's instructions. Forty-eight hours after transfection, the cells were diluted and selected in medium containing G418 (200 μg mL 1 ) for 14 d and then cloned using limiting dilution.
The selected clones were screened by Western blot and mixed clones from at least three independent clones were used in the following experiments.
Growth curves analysis
Cell growth curve was used to analyze the effect of overexpression of K-ras on the proliferation of Bxpc-3 cells. The cells were seeded in a 96-well plate with a destiny of 5000 cells each well. The cell number was detected every day by MTT assay as described before [15] . The absorbance was detected at 570 nm using a Multiskan GO microplate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Drug sensitivity assay
To compare the drug sensitivity in the established mutant clones, the following chemotherapy agents were used:
in water) and cisplatin (100 mmol L 1 in DMSO). Cells were seeded in 96-well plates as a density of 8000 cells per well and grew for 24 h. They were then exposed to various concentrations of chemotherapy agents for 48 h. The cytotoxicity effects of each drug on the growth of Bxpc-3 derived K-ras mutant clones were evaluated using MTT assay. Data are presented as mean±SD of three independent experiments.
Apoptosis analysis
Bxpc-3 cells were cultured in 6-well plates and treated with different chemotherapeutic agents for 48 h. Apoptotic cells were then identified by dual staining with FITC-conjugated with Annexin V and propidium iodide (PI) following the manufacturer's protocol (BD biosciences, San Jose, CA, USA). Briefly, the collected cells were washed twice with PBS. Then, cells were incubated with Annexin V-FITC and then PI for 15 min in the dark at room temperature. Cells were then analyzed within 1 h using flow cytometry (FACS Calibur, Becton Dickinson, Franklin Lakes, NJ, USA) and a computer station running Cell-Quest software (Becton Dickinson, Franklin Lakes, NJ, USA). Meanwhile, stained cells were captured by a cooled CCD camera (Leica DMI4000D, Wetzlar, Germany) coupled to the microscope.
Western blot analysis
For Western blot analysis, cells were cultured with RPMI1640 with 0.1% FBS for 24 h, followed by stimulated by 10% FBS for 30 min. Protein was extracted using RIPA lysis buffer (Beyotime, Shanghai, China) with PMSF (final concentration 1 mg mL 1 ; Beyotime) and Protease Inhibitor
Cocktail Set III (final concentration 5 μL mL 1 ; Merck KGaA, Darmstadt, Germany), followed by boiling at 95°C for 10 min with SDS-PAGE loading buffer (Beyotime). The proteins were separated in a gel containing 10% acrylamide. After electrophoresis, the separated proteins were transferred to PVDF membranes using 200 mA for 30 min (K-Ras and GFP) or 60 min (β-Actin, Akt and Erk) according to the molecular weight of proteins. The membranes were blocked with 5% BSA in Tris-buffered saline with 0.1% Tween 20 for 1 h. After that, they were incubated with primary antibodies overnight at 4°C. The following antibodies were used in our experiments: monoclonal mouse anti-phospho-Erk (Thr 202/Tyr 204), monoclonal rabbit anti-phospho-Akt (Ser473) antibodies (Cell Signaling Technology, Danvers, MA, USA); monoclonal mouse anti-GFP for both GFP (27 kD) and K-Ras-GFP fusion protein (48 kD), monoclonal rabbit anti-Akt, monoclonal rabbit anti-Erk antibodies (Beyotime); monoclonal mouse anti-K-Ras (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing in TBST for four times, the membranes were incubated with secondary antibodies for 1 h. After that, the membranes were washed again in TBST for three times, followed by detecting using ECL plus (Beyotime). Images were captured with the Alpha Innotech imaging system (CA, USA).
Statistical analysis
Data are expressed as the mean±SD with three replicates at least. One-way ANOVA followed by LSD multiple comparison was used to compare cell response to drugs between different groups, and P<0.05 was considered to be significant.
Results
Stable expression of different types of mutant K-ras in Bxpc-3 cells
The different types of K-ras cDNA were successfully inserted into pAcGFP1-C3 plasmid (5.2 kb) identified by BamH I and Xho I digestion and electrophoresis. The amplification product of full-length K-ras gene (576 bp) from K-Ras-pAcGFP1-C3 plasmid was also verified by agarose gel. Plasmids with WT and four mutant K-ras genes were successfully transfected into human pancreatic cancer cell line Bxpc-3. Western blot analysis indicated that the K-RaspAcGFP1-C3 transfected cells expressed a 48 kD K-Ras-GFP fusion protein, while the vector transfected cells expressed solely GFP protein (27 kD) ( Figure 1A ). In addition, Bxpc-3 also showed endogenous WT K-ras expression (21 kD), and overexpressed K-Ras-GFP fusion protein did not seem to change the expression of endogenous K-Ras. The vector transfected cells grew a little faster than the K-Ras-pAcGFP1-C3 transfected cells. In all five picked K-ras overexpressed clones, the K-Ras (G13D)-pAcGFP1-C3 transfected cells grew slower than all the other clones. In addition, the WT and other mutant clones showed comparable in vitro growth ( Figure 1B ).
Drug sensitivities of chemotherapy agents in Bxpc-3 derived clones expressing different K-ras mutations
MTT assay was performed to determine the role of K-ras mutation on the sensitivities of chemotherapy agents. For the EGFR tyrosine kinase inhibitors (EGFR-TKIs), the expression of mutant K-ras was associated with obvious resistance to gefitinib, while showed no reduced sensitivity to erlotinib (Figure 2A and B) . For the cytotoxic agents, the mutant clones showed obvious resistance to gemcitabine, 5-FU, and docetaxel compared with the WT clone ( Figure  2C-E) , whereas the response to cisplatin was not changed ( Figure 2F) . Moreover, the expression of a specific K-ras mutation induced a different drug sensitivity pattern. Specifically, the expression of G13D was associated with a strong resistance to gemcitabine and docetaxel, whereas the expression of G12V resulted in a remarkably reduced response to gefitinib and 5-FU.
Apoptosis analysis of chemotherapy agents in Bxpc-3 derived clones expressing different K-ras mutations
To determine whether apoptotic cell death is responsible for the reduced sensitivity to gefitinib, 5-FU, and docetaxel, we performed flow cytometry analysis with Annexin V and PI staining. Cells were treated with gefitinib (20 µmol L 1 ), 5-FU (10 µmol L 1 ), and docetaxel (0.01 µmol L 1 ) for 48 h.
The results showed that the apoptosis rate of gefitinib in K-ras G12D clone was significantly decreased compared with the WT clone, while the apoptosis rate of 5-FU was obviously lower in K-ras G12V clone (Figure 3) . In addition, the induction of apoptosis by docetaxel was reduced in both G12V and G12D mutant cells. These results suggested that the sensitivity to chemotherapy agents was reduced in K-ras mutant cells mainly by decreasing induced tumor cell apoptosis.
K-Ras downstream signaling in Bxpc-3-derived clones expressing different K-ras mutations
To determine if the overexpression of K-Ras can activate its downstream signaling, we analyzed the levels of p-Akt and p-Erk using Western blot. As shown by the results, the relative expression of p-Akt was up-regulated in K-ras G12V clone, while the levels of p-Erk was significantly higher in K-ras G12V, G12R and G12D clones (Figure 4 ).
Discussion
K-ras oncogene mutation is present in 90% pancreatic adenocarcinoma, but its role in the response of chemotherapy agents is unclear. In this study, we generated K-Ras overexpressing clones with the four most common amino acid substitutions (G12D, G12R, G12V and G13D) from the human pancreatic cancer cell line Bxpc-3 with a WT egfr and K-ras. Except for the K-ras (G13D) clone, the other mutant clones and WT clone showed similar in vitro growth.
As expected, the expression of mutant K-ras induced an excessive activation of downstream signals p-Akt and p-Erk. Specifically, expression of G12V mutant K-ras resulted in activation of p-Akt, while the K-ras G12V, G12R, and G12D clones showed obvious up-regulation of p-Erk than the WT clone. Similar results were reported in many other transfected cancer cell lines. Toulany et al. [16] reported that overexpression of G12V mutant K-ras strongly enhanced Akt phosphorylation in human breast cancer SKBr3 cells. Similarly, Minjgee et al. [17] reported that transfection of G12V mutant K-ras not only increased the expression of p-Akt, but also enhanced Erk phosphorylation in head-and-neck cancer FaDu cells. Moreover, expression of G12D mutant K-ras was reported to be able to promote activating of both PI3K and Erk activities in human pancreatic E6/E7/st cells [18] . Further, the present study also revealed the differences in the downstream activation by different types of K-ras mutation in human pancreatic Bxpc-3 cells.
Recent clinical studies have suggested that the K-ras mutation may be a negative predictor of response to the anti-EGFR monoclonal antibody in colorectal cancer, but the influence of K-ras mutations on the therapeutic efficacy of EGFR-TKIs is still debating. In the present study, the sensitivity to gefitinib was reduced in K-ras G12V and G12D mutant Bxpc-3 clones compared with WT clone, while the response to erlotinib was not influenced by K-ras mutation. Gefitinib and erlotinib are both reversibly competitive inhibitors of the tyrosine kinase domain of EGFR, but the present study implied the difference in the anti-cancer effects between the two EGFR-TKIs. The resistance to gefitinib in G12V and G12D clones may be partly explained by the excessive activation of K-Ras downstream signaling p-Akt and/or p-Erk. However, the phosph-Erk was also up-regulated in G12R clone, but the sensitivity to gefitinib was not changed. Therefore, the exact mechanism for the difference in the sensitivity to gefitinib in different types of K-ras mutant cells may warrant further study.
In our study, we also compared the sensitivity to the cytotoxic agents in WT or different mutant clones. Compared with the WT clone, drug resistance to gemcitabine was observed in the G13D clone, while the reduced sensitivity to 5-FU and docetaxel was found in the G12V, G12D, and G13D clones. However, there was no influence of K-ras mutation on the response to cisplatin. This phenomenon may be partly due to the increased phosph-Akt and/or phosph-Erk in mutant clones. As Baneriee et al. [19] reported, the reduction in p-Erk contributed to the reduced sensitivity of pancreatic ductal adenocarcinoma (PDAC) to gemcitabine. Over-expressed p-Erk was also reported to enhance the drug resistance to 5-FU [20] and docetaxel [21] . More interestingly, the expression of a specific K-ras mutation induced a different sensitivity pattern to 5-FU, docetaxel and gemcitabine in Bxpc-3 cells. Specifically, the G13D mutant clone showed a strong resistance to gemcitabine, 5-FU and docetaxel. Additionally, the expression of G12V and G12D mutant K-ras was associated with a remarkably reduced response to 5-FU and docetaxel. The Annexin V/PI staining assay also demonstrated that the apoptosis of 5-FU, and docetaxel was also reduced in K-ras G12D and G12V clones. Previous study also demonstrated that different types of K-ras mutation could also affect drug sensitivity in non-small-cell lung cancer cells [22] . But the response pattern to cisplatin and gemcitabine in non-smallcell lung cancer was different from the pattern in pancreatic cancer. The relationship between K-ras mutation and chemotherapy response may be different depending on tumor types, which needs further investigation.
In conclusion, we successfully constructed the recombinant eukaryotic expression plasmids containing different types of mutant K-ras genes. The mutant K-ras genes were stably expressed in Bxpc-3 cells. Expression of mutant K-ras significantly reduced the sensitivity of Bxpc-3 cells to gefitinib, 5-FU, docetaxel and gemcitabine, whereas showed no effect on erlotinib and cisplatin. More interestingly, different types of K-ras mutations could lead to a different pattern of drug sensitivity. Our study has provided preliminary data for further investigation on the effect of different K-ras mutations on the clinical efficacy of chemotherapeutic agents in pancreatic cancer. This may be important for the selection of effective clinical treatment.
